Category Archives: Public Policy

Latest From Public Policy

Twitter Twang: January 26 2010

Here’s today’s Twitter Twang: @Dialed_In Bio Ohio launches scholarship program… http://dialedin.org/?p=2236 @sanera09 A New Way to Look for Diseases’ Genetic Roots http://www.nytimes.com/2010/01/26/science/26gene.html @MassHighTech: Women to Watch winners list, virtual world startup top our most-read stories of the past week:http://bit.ly/MHTRead @SoCalBio Weekly Update (Jan 25, 2010) available now at http://bit.ly/d1ShRH @jamie_love The German Association for the Protection of Intellectual Property (GRUR) was surprisingly cool at WIPO SCP this week. http://www.grur.de/ @CharlieRoseShow Tuesday 1/26 -Harrison Ford discusses his film “Extraordinary Measures” Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Today’s Twitter Twang – January 25, 2010

Today’s Twitter Twang, a summary of biotechnology and intellectual property news on Twitter.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags:

Tomorrow Morning on NPR: BIO, ACLU Discuss Gene Patenting

You can listen from your desk at http://www.wbur.org/listen. Callers will have the opportunity to ask questions after the first 20 minutes. If you’re interested in the topic, you can find background material on gene patenting at http://bio.org/ip/genepat/ and our amicus brief in the ACLU lawsuit is posted at http://bio.org/ip/amicus/documents/BIOAmicusBriefACLU-Myriad12-09.pdf.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

IP Professors: 12-Year Data Exclusivity a Win-Win for Patient Access & Biotech Innovation

David E. Adelman of the University of Texas School of Law and Christopher M. Holman of the University of Missouri – Kansas City School of Law recently published analysis on the “sideshow” of the data exclusivity debate in Washington.

Adelman and Holman use a cost-benefit analysis that incorporates the most important legal precedents and case law today in concluding that “policymakers should focus on mitigating the systematic barriers to entry that pose much greater and longer-term obstacles to lower-cost biotech drugs.” Specifically, the draft paper provides solid analysis of the need for 12-year data exclusivity, which the authors describe as a perfect balance between providing access to important medicines to patients, and creating the incentives needed for investors and companies to prepare (and survive) the regulatory approval process for follow-on biologics.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Technology Transfer Symposium Presentations Published

You can access all the presentations from the Technology Transfer Symposium, held in October 2009 at the BIO Investor Forum, by visiting http://bio.org/ip/techtransfer/. For more information, you can contact Margarita Noriega, Coordinator of Bioethics & IP Policy, at mnoriega@bio.org.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: